Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569126 | 0.87 | CYSLTR2 (0.45) | CYSLTR2CYSLTR1ALDH1A1LTB4R | |
| SCHEMBL4569127 | 0.87 | LTB4R (0.42) | CYSLTR2CYSLTR1ALDH1A1LTB4R | |
| SCHEMBL4569128 | 0.87 | L3MBTL1 (0.45) | CYSLTR2CYSLTR1L3MBTL1ALDH1A1LTB4R | |
| SCHEMBL16572770 | 0.85 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1FAAHPFKFB3MAPK1 | |
| SCHEMBL4569133 | 0.84 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1MAPK1ALDH1A1TSHR | |
| SCHEMBL13881831 | 0.83 | CYSLTR2 (0.43) | CYSLTR2CYSLTR1FAAHPFKFB3MAPK1 | |
| SCHEMBL4569132 | 0.82 | MAPK1 (0.40) | CYSLTR2CYSLTR1MAPK1ALDH1A1TSHR | |
| SCHEMBL2208832 | 0.81 | PFKFB3 (0.42) | CYSLTR2CYSLTR1FAAHPFKFB3MAPK1 | |
| SCHEMBL12433012 | 0.76 | ADRB2 (0.41) | CYSLTR2CYSLTR1MAPK1ALDH1A1TSHR | |
| SCHEMBL3704874 | 0.74 | CACNA1B (0.47) | PFKFB3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CYSLTR2 455/4885CYSLTR1 420/4885FAAH 1676/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYSLTR2 456/4885CYSLTR1 417/4885FAAH 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.